Feasibility and Acceptability of Somatocognitive Therapy in the Management of Women with Provoked Localized Vestibulodynia - ProLoVe Feasibility Study

Mette Bøymo Kaarbø (✉ metteboy@oslomet.no)

Oslo Metropolitan University: OsloMet - storbyuniversitetet <https://orcid.org/0000-0002-5879-8188>

Kristine Grimen Danielsen

Oslo Metropolitan University Faculty of Health Sciences: OsloMet - storbyuniversitetet Fakultet for helsevitenskap

Gro Killi Haugstad

Oslo Metropolitan University Faculty of Health Sciences: OsloMet - storbyuniversitetet Fakultet for helsevitenskap

Anne Lise Ording Helgesen

Oslo University Hospital: Oslo Universitetssykehus

Slawomir Wojniusz

Oslo Metropolitan University Faculty of Health Sciences: OsloMet - storbyuniversitetet Fakultet for helsevitenskap

---

Research

Keywords: provoked vestibulodynia, vulvodynia, vestibulitis, somatocognitive therapy, feasibility study

Posted Date: June 30th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-661042/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Pilot and Feasibility Studies on March 23rd, 2022. See the published version at <https://doi.org/10.1186/s40814-022-01022-2>.

Abstract

Background: Provoked vestibulodynia (PVD) is a prevalent chronic pain condition especially among young women. Pain is localized to the vulvar vestibule and is provoked by touch or pressure, such as penetrative intercourse. PVD can have profound consequences, adversely affecting a woman's sexual life, relation to her partner and her psychological health. There is an urgent need for well-designed randomized clinical trials (RCTs) to identify the most effective interventions for this neglected women's health condition.

Aims: The primary aim of this study is to assess the feasibility of undertaking a full-scale RCT of somatocognitive therapy (SCT), a multimodal physiotherapy intervention, for women with PVD. The secondary aim is to evaluate implementation and acceptability of SCT and its potential treatment effectiveness in PVD. In the full-scale RCT SCT will be compared to standard PVD treatment.

Methods: This multi-method feasibility study utilized a single subject study design with nested qualitative data. Ten women with PVD, aged 18-35, were recruited from the Vulva Clinic at Oslo University Hospital. The intervention took place at Oslo Metropolitan University. Participants were assessed at baseline, post-treatment and at the eight month's follow-up with the tampon test and self-report questionnaires. The main feasibility outcomes were evaluation of recruitment rate, adherence to assessment tools and follow-up rate. The participants' experiences with the primary outcome and the intervention were explored with semi-structured interviews.

Results: Ten out of 18 eligible patients were recruited over 11 weeks. None were lost to follow-up. Adherence to self-report questionnaires was excellent. Adherence to tampon tests and to the reporting of treatments was good, whereas adherence to the 14-day diary was poor. No adverse events were reported. The tampon test was suboptimal as a primary outcome. SCT was found to be an acceptable treatment based on Global Perceived Effect scores and the participants' experiences.

Conclusion: The findings suggest that it is feasible to deliver a full-scale RCT of the SCT intervention for women with PVD. Some changes are suggested to optimize the protocol, such as increasing recruitment sites, change of primary outcome measure and adding a booster session.

Trial registration: ClinicalTrials.gov NCT04208204, Registered December 23, 2019 – Retrospectively registered, <https://clinicaltrials.gov/ct2/show/NCT04208204>

Key Messages

What uncertainties existed regarding the feasibility?

We wanted to investigate the recruitment and follow-up rates, adherence to outcomes, the primary outcome measure, adverse events, as well as the acceptability of SCT.

What are the key findings?

- Follow-up rate, adherence to most outcomes, acceptability to SCT were judged to be feasible
- The tampon test is suboptimal as a primary outcome in PVD
- The feasibility of the recruitment was below the expected level

What are the implications of the findings for the design of the main study?

The findings suggest that it is feasible to deliver full scale RCT of the SCT intervention in this population, with some adjustments to the protocol:

- Include additional recruitment sites to optimize recruitment
- Replace the tampon test with the Female Sexual Function Index as a primary outcome
- Include a booster session six months post treatment

Background

Vulvodynia is a multifactorial vulvar pain condition of unknown cause. In the general population, the lifetime prevalence of vulvodynia is estimated between 7 and 16% (1–3) with a higher incidence amongst young women (4, 5). Although prevalent, vulvodynia is a neglected women's health condition, where empirically supported treatment guidelines are still lacking (6). The most common subtype of vulvodynia is provoked vestibulodynia (PVD) (7). In PVD, pain is localized to the vulvar vestibule and is provoked by touch or pressure such as sexual intercourse and tampon insertion. This pain condition represents the most common cause of painful intercourse (7, 8), adversely affecting women's quality of life (9–12), psychological health (13, 14) and relation to their partners (15).

The management of PVD is complex and challenging with several treatments available, including pharmacotherapy, surgical, physiotherapy and psychotherapy. Research evidence, however, is scarce regarding which treatment approach is the most effective. Although physiotherapy is a common first-line treatment for PVD, a systematic review highlighted the need for well-designed randomized controlled trials (16). Traditionally, physiotherapy treatments for PVD range from internal (vaginal) to external soft tissue mobilisations, joint manipulation, electrotherapy, therapeutic exercises and pelvic floor exercises (17). A recent multicenter randomized clinical trial (RCT) also found multimodal physiotherapy to be effective in the management of PVD (18).

Somatocognitive therapy (SCT) is an existing multimodal physiotherapy intervention developed at Oslo University Hospital, Norway, in an attempt to alleviate the burden of longstanding pelvic and gynecological pains (19–21). In recent years, SCT has been modified and further developed to treat women with PVD, based on experiences from a pilot study (22), from PVD patients (23) and physiotherapy students treating PVD patients (24). Whereas multimodal physiotherapy treatments are usually provided by physiotherapists specialized in women's health, SCT is intended to be implemented in primary care and designed to be easy to learn. Furthermore, this approach differs from other forms of physiotherapy for PVD by focusing somewhat less on pelvic floor rehabilitation. SCT is designed to target

the multiple dimensions of vulvar pain utilizing a biopsychosocial approach, where the overall aim is to explore and improve body awareness, reduce vulvar pain and improve sexual function. Other essential components include cognitive strategies to improve coping with negative emotions and thoughts, and structured exposure to pain associated activities. In a recent systematic review on psychosocial factors a broader approach to PVD was supported (25).

The primary aim of this **Provoked Localized Vestibulodynia (ProLoVe)** feasibility study is to assess the feasibility of undertaking a full-scale RCT of the SCT intervention for women with PVD. In the full-scale RCT, SCT will be compared to standard PVD treatment, of which the latter can include women's health physiotherapy, topical or oral medication, sex therapy and/or psychological counseling. The main feasibility objectives will evaluate the recruitment rate, the follow-up rate, adherence to the data collection procedure and number of adverse events. In addition, this study will evaluate the tampon test (26) as a primary outcome measure in preparation for the main trial. The secondary aim is to evaluate implementation and acceptability of the intervention for the participants and to assess if SCT has the potential to reduce pain, pain catastrophizing and psychological distress, as well as improve sexual function.

Methods

Study design and procedure

This multi-method feasibility study consisted of a single subject study design with nested qualitative data. Ten participants were recruited (February to April 2019) from the Vulva Clinic, Department of Obstetrics and Gynecology, at Oslo University Hospital (OUH)). The SCT intervention took place in the outpatient clinic at the department of physiotherapy, at Oslo Metropolitan University. The trial consisted of three evaluation points: pre-treatment, post-treatment and eight months follow-up. In addition, the participants were interviewed twice; towards the end of the treatment period and one year later.

Participant's eligibility assessment was based on a comprehensive gynecologic examination and medical history using a standardized protocol for PVD diagnosis (27). Norwegian speaking women, aged 18–35, diagnosed with PVD, experiencing pain during 1) penetrative intercourse, 2) pressure applied to the vulvar vestibule or 3) usage of tampons, were eligible. Patients with an active infection or dermatologic disease in the vulvar region were excluded. Eligible patients were verbally informed about the study and received an information leaflet at the Vulva Clinic. Ten out of 18 eligible women contacted the primary investigator (last author) and received a detailed explanation about the study. All ten agreed to participate. Eight women however did not contact the primary investigator and reasons for this is unknown. Flow of participants through the study is presented in Fig. 1. This study is not intended to be fully powered for detection of statistically significant effects. The research team therefore decided that ten participants would be an adequate sample size to give a preliminary understanding of the feasibility of undertaking a RCT of the SCT intervention.

Research ethics

The Regional Committee for Medical and Health Research Ethics in South East Norway (ref. no. 2018/1036, 01.10.18) approved the project. The trial was also registered at ClinicalTrials.gov under the identifier NCT04208204. All participants provided written informed consent prior to participation in this research. The trial is reported according to the Consolidated Standards of Reporting Trial (CONSORT) 2010 statement: extension for pilot/feasibility studies (Additional file 1) (28).

Data collection

All quantitative data were collected via electronic forms and directly transferred in a secured manner to the Services for Sensitive Data (TSD) research server. Qualitative interviews were recorded with Dictaphone app, which insured immediate and direct transfer of the files to the TSD research server. The qualitative data collected through interviews was transcribed verbatim and uploaded into NVivo 12.

The patients received several electronic assessment packages throughout the study. There were three main assessment time points, baseline, post treatment and eight months follow-up.

Assessment packages at baseline, post treatment and eight months follow-up

Assessment package 1

The participants received an electronic link to the main questionnaire package which included sociodemographic and clinical characteristics and a battery of self-reported questionnaires including Female Sexual Function Index (29), Pain Catastrophizing Scale (30) and Hopkins Symptom Check List-25 (31). Details of these measures are included in additional file 2. Information about age, number of children, relationship status, education, work status, use of analgesics, body mass index, exercise and intercourse frequency in the last four weeks was collected at baseline.

Assessment package 2

baseline tampon test undertaken in the evening on day 1, 7 and 14 to measure vulvar pain intensity using the Numeric Rating Scale (NRS) (0–10), where a score of zero represented no pain and 10 meaning the worst possible pain.

Assessment package 3

a 14-day diary (32), an *index of emotional instability*, to assess day to day variance in emotional states.

Registration of received treatment

Assessment package 4

Participants received bi-weekly electronic forms up until the 8 months follow-up recording all treatments received for PVD in the past 14 days. This included all visits to various health professionals, use of medication and number of sick leave days. In the full-scale RCT this information will be used to determine what kind of treatments the participants will be receiving and to conduct cost-effectiveness analysis.

Tampon test as primary outcome measure

One of the aims of this feasibility study was to evaluate the tampon test as the primary outcome measure. The tampon test was chosen as a primary outcome based on recommendations for self-report outcome measures in vulvodynia clinical trials (33). This test has been used as a primary outcome measure in various clinical trials for vulvodynia, evaluating the effect of various treatments (34–40). It is an alternative measure for pain associated with vulvovaginal penetration and allows the inclusion of women with PVD who are unable to have intercourse. The test has demonstrated good construct validity and reliability (26). In this study, all women were provided with the same type of tampon as the validity study, the original Regular Tampax™ Tampons (26). Participants were provided with detailed instructions about how to undertake and record the tampon test, as described by Foster et al (2009). The participants recorded the degree of pain on the entire tampon insertion and removal experience on the NRS.

Qualitative interviews

All participants were interviewed one-to-one towards the end of the treatment period. Seven of the women also agreed to take part in a follow-up interview one year later. A phenomenological worldview informed the qualitative approach, where the aim was to explore and give voice to the subjects' perspectives and lived experiences (41). The second author, a female physiotherapist experienced with qualitative interviews conducted the interviews and was not involved in the delivery of the treatment. During the first round of interviews, each interview took place in the physiotherapy outpatient clinic at Oslo Metropolitan University. The second interview round was conducted using Zoom, a video meeting platform, due to the Covid-19 restrictions. Each interview lasted 60–90 minutes. A semi-structured interview guide was used to ensure each area of interest was addressed during the interviews, while at the same time encouraging the women to speak freely about their experiences (41). The interviewer introduced the central topics with open-ended questions, asking the participants to share their experiences with the outcome measures and their experiences with SCT. To elicit rich descriptions, the interviewer tried to follow up salient cues and themes in the participants' answers, inviting them to elaborate, provide examples, or to clarify where appropriate. The interviewer was on the lookout for variations, different angles and conflicting viewpoints, to promote a nuanced data material (41).

Intervention

In recent years, SCT has been developed to treat women with PVD (23, 24, 42–44). SCT is a multimodal physiotherapy treatment approach previously shown to be effective in the treatment of chronic pelvic pain (19–21). In Table 1 an overview of the intervention is presented as it was provided in this trial,

utilizing the template for intervention description and replication TIDierR (45). The intervention was conducted by the first author, an experienced female physiotherapist trained in SCT.

Table 1

Overview of somatocognitive therapy as provided in the feasibility study, as per TIDierR Criteria

TIDierR Items (45)	Description
Brief name	Somatocognitive therapy for Provoked Localized Vestibulodynia (ProLoVe feasibility study)
Why	Few RCTs exist, important to develop effective treatments that can easily be applied in primary care. Running a feasibility study is important in preparation for full-scale RCT.
What	SCT is a multimodal physiotherapy intervention designed to target the multiple dimensions of vulvar pain utilizing a biopsychosocial approach. A bodily approach is combined with cognitive restructuring of negative thoughts. Overall, the aim is to improve body awareness to reduce vulvar pain and psychological distress and improve sexual function.
Materials; Participants	Resources: vulva.no
Materials; Physiotherapist	Equipment included a treatment bench, mat, pillows, massage balls, mirror, Pilates ball and education material.

TIDierR Items (45)	Description
Procedures	Initial appointment: Assess participant – take a thorough history (including previous experiences, beliefs and expectations) and clinical examination, (quality of movement, breathing pattern). The main areas of SCT include: Therapeutic alliance is an essential component of SCT; patient and therapist are in a close working relationship, agreeing on treatment goals and home assignments. Participants take an active part in the decision-making process about their own treatment and progression. The bodily approach: breathing patterns, maladaptive movement and postural patterns are addressed in various positions (sitting, standing, walking and in supine). Through manual techniques and touch participants are taught various techniques to increase body awareness, improve relaxation and reduce muscle tension. Education about PVD, chronic pain, stress and healthy vulvo–vaginal and sexual behaviors. Coping with emotions and thoughts related to bodily experiences. Participant learns to become aware of negative/catastrophizing thoughts and learns how to restructure or accept these thoughts as well as how to overcome fear avoidance behavior. An important aspect is the women’s ability to adapt and to self-manage their condition such as coping with pain and flare-ups. Structured homework promoting the application of learned techniques in daily situations. Gradual exposure to activities associated with pain, desensitization exercises and exercises to increase pelvic floor and vulva awareness. Relaxation and breathing exercises. Last session – create a self-management toolbox with participant
Who provides	Experienced female physiotherapist trained in SCT, first author of article.
How	Each session has a three phased structure: 1) The conversation, 2) the bodily intervention/exploration and 3) the home assignment.
Where	In a closed room with access to gym, outpatient physiotherapy clinic, Oslo Metropolitan University, Norway Home assignments performed by the participants integrated into ADL
When and how much	Initial appointment offered to patients after collection of baseline data Median number of sessions: 12 (min 7; max 15) face to face with physiotherapist, Treatment period: minimum 13 weeks and maximum 22 weeks Each session (including initial session), lasted up to 60 minutes. The number of sessions required was personalized.
Tailoring	The treatment is personalized and tailored to the individual. Patient participation and collaboration is important. The treatment principles are the same for all but are adapted to suit the individual’s needs.

Study outcomes

Primary feasibility outcomes

The primary aim of this study was to evaluate the feasibility of undertaking a full-scale RCT of SCT for women with PVD. This trial measured several feasibility outcomes in preparation for the main trial. These included:

- **Recruitment rate.** This was defined as the number of eligible patients and number of recruited participants per week within a period of five months.
- **The follow-up response rate.** This was measured by the percentage of participants who were followed up successfully until the eight months follow-up.
- **Adherence to completion of outcomes.** Adherence was defined as the number of participants who fully completed the battery of self-reported questionnaires, the 14-day diary, the number of performed tampon tests and biweekly forms about the received treatment, within a time frame of eight months.
- **Evaluation of the utility value of the tampon test** as a primary outcome measure based on tampon test data and the participant's experiences with the tampon test (reported in separate mixed methods study (46).
- **Reporting of adverse events.** An event was recorded as adverse if a participant was pulled out of the study because SCT was deemed as an inappropriate treatment.

Secondary outcomes

The secondary aim of this study was to test the implementation and acceptability of the somatocognitive intervention utilising both quantitative and qualitative data. The 6-point Global Perceived Effect (GPE) scale was used to provide quantitative estimation of participants' perceived effect with the treatment directly after treatment and at the eight months follow-up (47). The participants were asked "Overall, how much did the treatment you received help your problems?". The scale ranges from one to six; very much better, much better, a little better, no change, much worse and very much worse. During the semi-structured interviews, participants were asked about their experiences with SCT intervention, both towards the end of the treatment period and one year later. In addition, the aim was to evaluate if SCT has the potential to reduce pain, pain catastrophizing and psychological distress, as well as the potential to improve sexual function. A description of the self-reported outcome measures is provided in additional file 2.

Data analysis

For the feasibility analysis, the results will be expressed as numbers referring to recruitment rate, follow-up, adherence and adverse events respectively. Descriptive statistics were used to assess the feasibility objectives and the self-reported outcomes using SPSS (version 27, IBM, Armonk, NY, United States of America) and Microsoft Excel (2016). Due to the nature of a feasibility study and the low number of

participants, no hypothesis testing was performed, hence the continuous variables were presented with median and quartile values.

In the qualitative phase a semantic thematic analysis was performed by the interviewer (48). Attentive reading and re-reading of the transcripts helped to discern central aspects in the women's experiences and initial codes were identified. Taking care to include both common and diverging experiences, these initial codes were then reworked and organized into a map of themes and sub-themes related to experiences with outcome measures, the somatocognitive intervention and perceived benefits (included in additional file 3) The first and second author independently reviewed and revised the map for validity against the dataset until agreement between the authors was reached. The findings are presented as analytical summaries and illustrative quotes, which are fitted under relevant subheadings in the results section. All co-authors took part in the discussion of the final findings.

Results

Ten nulliparous women with PVD, median age 21 (18 to 33), participated in this feasibility study. The sociodemographic and clinical characteristics of the participants are presented in Table 2. Seven of the women reported different comorbidities including jaw pain, muscle pain and twitching, anal pain, endometriosis, headache, migraine, fibromyalgia, irritable bowel syndrome and alopecia areata. Overall, the women were physically active, exercising from one to three times per week for 30–60 minutes at moderate to high intensity levels. Only one reported never exercising. At baseline, four subjects were on oral contraceptives; one on cerazette, one on marvelon and two on oralcon. In terms of concurrent drug use all participants reported to have tried topical lidocaine. At baseline, six patients used topical lidocaine on a weekly to daily basis. In addition, one participant was on systemic treatment with amitriptyline, another on levothyroxine and one on diclofenac.

Table 2
Sociodemographic and clinical characteristics of ten women with provoked vestibulodynia

Characteristics	Participants n = 10
Age (<i>yrs.</i>), median (Q1; Q3)	21 (20; 26)
Pain duration (<i>yrs.</i>), median (Q1; Q3)	7 (3; 8)
Primary PVD	7
Relationship category	
Married/common law	2
In a relationship	2
Single	6
Childbirth	0
Intercourse past 4 weeks	2
Education category	
High school student	1
Undergraduate student	7
Completed bachelor's degree	2
Work category	
Student	9
Part time work	5
Full time work	1
Unemployed	0
Participants with comorbidities	7
BMI, median (Q1; Q3)	23 (20; 23)

Results of feasibility outcomes

Recruitment rate

Eighteen women were found eligible for participation, and ten women contacted the primary investigator and agreed to take part in the study. Ten participants were recruited over 11 weeks from the Vulva Clinic,

achieving a recruitment rate of 0.9 participants per week. Recruitment was stopped when the targeted sample of ten participants was reached.

Follow-up rate

No participants were lost to follow-up. All the participants completed the SCT intervention and all partook at all measurement time points up until the eight months follow-up.

Adherence to assessment procedures

Overall adherence to the battery of self-report questionnaires was excellent, with all participants completing all the self-reported questionnaires at all three time points. In terms of adherence to the tampon tests across the three measurement time points, 81 out of 90 tampon tests were completed (90%). At baseline, there were nine full tampon test sets. Post treatment there were eight full tampon test sets and at the eight months follow-up there were six full tampon test sets. For the 14-day diary there were six full data sets at baseline, three post-treatment and two at the eight months follow-up. Regarding adherence to the bi-weekly forms about received treatments, two women did not record any of the SCT treatments, however all the other treatments received were recorded.

Evaluation of the tampon test as the primary outcome measure

Evaluation of the tampon test is reported in a separate paper (46). We concluded that the test may be suboptimal as a primary outcome measure in PVD research. The tampon test data demonstrated large intra- and inter-individual variability, furthermore the test seems to underestimate severity of pain in some women with PVD. Out of ten women with PVD, four of the women had an NRS score that was equal to, or below four, whilst concurrently reporting high levels of pain during sexual intercourse. Participants with low pain scores would be excluded from studies where the tampon test is part of the trial eligibility criteria, even though severe pain was experienced during sexual intercourse. Several women also reported in the interviews that they experienced the test as an inadequate measure of their problem (46).

Reporting of adverse events

There were no adverse events reported, i.e. no participants were pulled out of the study because SCT was considered as an inappropriate treatment. All participants turned up for their scheduled appointments and completed the intervention.

Results of secondary outcomes

Implementation and acceptability of somatocognitive therapy

In this study the participants received a median number of 12 sessions. The SCT was personalized, hence the number of treatments delivered varied from seven up to a maximum of 15 sessions. In the original protocol, we stipulated that treatment duration would last for up to ten weeks. In this study, the treatment course lasted a minimum of 13 weeks and a maximum of 22 weeks. The frequency of the treatment

delivery varied as it was personalized to the individual's needs. Patients communicated to the therapist that they needed time to practice home assignments and incorporate what they had learnt into their ADL. Frequency of treatment was also influenced by external factors such as study and work commitments, exams, and holidays.

Half of the participants were content with the number of treatment sessions received and felt ready to continue by themselves when the treatment period ended. The other half reported that they would have preferred a slightly longer treatment period. Several found it more difficult to keep motivated to prioritize their recovery process when their progress was no longer monitored by the therapist. *P8: "Immediately after the treatment period ended it felt a bit tough. You receive such close guidance, and then you are suddenly alone with it again. I found it a bit difficult to keep my motivation up".* Most felt they would have benefited from one or two follow-up sessions a few months later, for repetition, motivation and guidance on how to move forward. *P3: "Perhaps it could have been possible with a follow-up session six months later, in case things should get worse or you need some repetition, or when things have just been a little too much."*

Participants' perceived effect of SCT

The GPE scale was used to provide quantitative estimation of participants' perceived effect of the treatment measured directly after treatment and at eight months follow-up. Directly after treatment three women reported to be *very much better*, four reported to be *much better* and three reported *a little better*. At eight months follow-up one participant reported to be *very much better*, six participants reported *much better*, two reported *a little better* and one reported *no change*.

Participants' experiences with the intervention

All participants expressed positive experiences with the SCT approach. They found it useful to learn techniques for deep breathing, relaxation, and self-management, as well as developing more constructive ways of thinking about and relating to their pain and sexuality. The participants largely expressed beliefs that PVD is complex and multidimensional in nature. They found it meaningful to combine physical and psychological aspects, and not exclusively focus on the painful vulvar area. *P3: "I feel that somatocognitive therapy is more focused on the long-term recovery process. That it is easier to get lasting results when you not only treat the local muscles or problem area, but also include everything else around".* Furthermore, the importance of taking responsibility for their own recovery process was expressed by *P6: "It makes so much sense that this is what I have to do. Not just talk about it and not just receive massage here or there. I have to make an active effort. Breathe. I have to relax".* Three participants however (*P2, P7 and P9*), felt the intervention would have benefitted from a specific focus on the vulvar area, including manual techniques to release tensions in the pelvic floor muscles. Most of the participants however, appreciated the gentle and desensitizing approach to the vulva. Several women also expressed that the encouragement to explore their own vulvas had helped them develop a more positive way of relating to this area. *P4: I feel like I have made great improvements as before my vulva felt very*

unfamiliar, I just didn't want to think about it. But now I actually feel that I have developed a completely different way of thinking about it and how it also is about being less afraid of the area".

The secondary aim of this study was to evaluate if SCT intervention had the potential to improve sexual function and reduce pain, pain catastrophizing and psychological distress. The women improved on all the outcome measures from baseline to post treatment, with a slight deterioration of the effect at the eight months follow-up. Table 3 includes all the measurements and number of participants who had experienced intercourse in the past four weeks, at the three time points.

Table 3

Measurements at baseline, post-treatment and 8 months follow-up (n = 10), (none lost to follow-up)

	Pre-treatment	Post-treatment	8 months follow-up
Tampon test NRS (0–10), median (Q1; Q3)	4.5 (2.5; 6)	2 (1.5; 4.2)	3.5 (1.8; 4.5)
Intercourse past 4 weeks, n	2	6	7
FSFI , median (Q1; Q3)			
Total sum (0–36)	14.8 (9.8; 19.8)	22.8 (15.8; 25.4)	20.9 (18; 27.1)
Desire	2.1 (1.6; 3.2)	3.6 (2.3; 3.8)	3.6 (2.7; 4.3)
Arousal	3.2 (1.6; 4.9)	4.4 (2.7; 5.7)	4.4 (3.0; 5.6)
Lubrication	4.2 (2.9; 5.2)	4.8 (3.5; 5.8)	4.7 (3.6; 6.0)
Orgasm	3.2 (0.9; 5.3)	4.8 (2.6; 5.3)	4.8 (1.2; 5.2)
Satisfaction	0.8 (0.4; 2.0)	4.2 (1.1; 5.2)	3.8 (1.2; 5.3)
Pain	0.0 (0.0; 0.3)	1.8 (0.0; 3.6)	2.0 (0.0; 3.6)
PCS (0–52) , median (Q1; Q3)	20 (15.3; 29.3)	9.5 (5.3; 20)	12.5 (6.3; 22)
HSCL-25 , median (Q1; Q3)	2.0 (1.7; 2.5)	1.6 (1.3; 2.4)	1.8 (1.6; 2.2)
NRS: Numerical Rating Scale; (higher scores indicate more pain) FSFI: Female Sexual Function Index (higher scores indicate better sexual function); PCS: Pain Catastrophizing Scale (higher scores indicate higher levels of catastrophizing); HSCL-25: Hopkins Symptom Check List – 25 (higher scores indicate higher levels of psychological distress).			

Discussion

This study was designed to assess the feasibility of running a full-scale RCT of the SCT intervention for women with PVD. In addition, the implementation and acceptability of SCT was evaluated, including its potential as a treatment for PVD. The current study demonstrated that the study was feasible with respect to follow-up rate and adherence to the assessment outcomes. We would argue that the intervention was

acceptable based on Global Perceived Effect scores, the participants' experiences with the intervention and the changes seen on the outcome measures. No adverse effects were reported. Based on the feasibility findings a few changes are suggested to optimize the protocol. In the following section the feasibility outcomes and secondary outcomes will be interpreted and further discussed.

In terms of recruitment for the study, ten out of 18 patients were recruited over 11 weeks from one site, achieving a recruitment rate of 0.9 participants per week. To run a fully powered RCT with 130 patients, recruited in approximately 24 months, we will have to expand recruitment sites to other gynecologists experienced with PVD located at various clinics in the Oslo area.

Feasibility outcomes related to follow-up rate and adherence was overall satisfactory. No participants were lost to follow-up and adherence to completion of the battery of self-reported questionnaires was excellent, with all ten participants fully completing the questionnaires. We demonstrated good adherence to the tampon test, with 81 out of 90 tampon tests completed (90%). Most of the missing tampon test data occurred at the eight months follow-up. The 14-day diary however, the *Index of emotional instability*, which was used to measure day-to-day variance in emotional states, had high levels of missing data. At the eight months follow-up there were only two complete 14-day diary sets, hence the diary will not be included in the main trial. During the interviews, many women found the diary time consuming and difficult to remember, and for some it also felt irrelevant. Adherence to the reporting of received treatment was satisfactory with eight full sets at the eight months follow-up. Two women did not record any of the physiotherapy treatments received, possibly due to a misunderstanding as all the other treatments they had received had been recorded.

A further aim with this study was also to evaluate the feasibility of using the tampon test as a primary outcome measure. Many women with PVD abstain from penetrative intercourse and have difficulties with reporting pain. The tampon test was therefore chosen as a primary outcome measure as it was specifically designed to address this challenge (26). Based on the tampon test data and the participants' experiences with the test and input from a user representative, we concluded in a separate paper (46) that the tampon test is suboptimal as a primary outcome measure in PVD research. Therefore, in the upcoming RCT, the primary outcome measure will be the Female Sexual Function Index (FSFI), while the tampon test will be applied as a secondary outcome. FSFI is widely used in PVD research (18, 49, 50). In addition to pain experienced during intercourse, it captures several other dimensions of sexual functioning. In this study the participants improved on average by 7.9 points (from 14.8 to 22.7 post treatment) and 6.1 points (from 14.8 to 20.9) at the eight months follow-up, when accounting for all subscales on the FSFI. We observed very similar magnitude of changes on all subscales, which conforms to the notion of a multidimensional nature of this disorder. In preparation for the upcoming main trial, the choice and implementation of outcome measures, including the FSFI, will be based on the findings from this feasibility study and *Recommendations for the study of the vulvar pain in women, part I: review of assessment tools* (51).

Overall, we would argue that SCT is an acceptable and promising intervention. These findings are in line with previous studies evaluating the effect of SCT for women with chronic pelvic pain (19–21) and women with PVD (22). SCT is designed as a short-term therapy where one of the goals is to promote self-management of PVD and avoid over-treatment and therapist-dependency. Although approximately half the women were satisfied with the amount of treatment received, some expressed that the treatment ended too soon and described how a booster session would be valuable. This would provide an opportunity to receive support and guidance over time. Consequently in the future RCT, the participants will be offered one booster-session six months after the end of the treatment.

Participants perceived effect was measured with the GPE and was further supported by the qualitative interviews with most women reporting a variety of improvements following the SCT intervention. In terms of pain reduction, most women described a recovery process characterized by periods of improvements and setbacks, but overall experienced a positive development. Meaningful changes also included improved body awareness; an improved ability to relax, feel more connected and comfortable in their own bodies. Several of the participants also described how the intervention had helped them develop a more neutral and less fearful way of thinking about their pain, which was also supported by the findings on the pain catastrophizing scale. Furthermore, the women had gained more healthy attitudes and strategies regarding their sexuality and some felt more confident involving their romantic partner in the recovery process.

This study allows us tentatively to assess the effectiveness of the intervention in a small sample of participants. This study was not powered to detect changes over time and results should therefore be interpreted with caution. Albeit, all outcome measures pointed in the same direction, as the participants improved on the primary outcome, i.e. the tampon test, and all the secondary outcomes in the main questionnaire packet following SCT. The results indicate that the intervention has potential treatment effectiveness in a small sample of participants with PVD.

Limitations of this study were the small sample and the lack of an active control group. In the main trial the SCT will be compared to standard treatment. A control group could have provided us with valuable information about the treatments delivered in this group, as well as the feasibility of the randomization process. The strength of this study is that both quantitative and qualitative methods were implemented to evaluate the feasibility and acceptability of SCT.

Conclusion

We conclude that it is feasible and practical to deliver a RCT of SCT, a multimodal physiotherapy intervention, in women with PVD. The aims of the feasibility study have been met, however some changes are suggested to optimize the study protocol, before conducting a full-scale RCT. This includes replacing the tampon test with the FSFI, increasing the recruitment sites and adding a booster session.

Abbreviations

FSFI: Female Sexual Function Index; HSCL-25: Hopkins Symptom Check List – 25; NRS: Numeric Rating Scale; PCS: Pain Catastrophizing Scale; PVD: Provoked Vestibulodynia; RCT: Randomized Clinical Trial; SCT: Somatocognitive Therapy

Declarations

Ethics approval and consent to participate: The Regional Committee for Medical Research Ethics in South East Norway (ref. no. 2018/1036) approved the project before the trial began. All patients gave their written informed consent after being provided verbal and written information. The trial adheres to the Declaration of Helsinki.

Consent for publication: Consent to publish results were obtained from all participants.

Availability of data and material: Anonymised individual-patient datasets are available from the corresponding author on reasonable request.

Competing interests: The authors declare that they have no competing interests.

Funding: Funding from Oslo Metropolitan University and the Norwegian Fund for Post-Graduate Training in Physiotherapy. The funding bodies had no role in the design of the study and collection, analysis and interpretation of data or in the writing of the manuscript.

Authors' contributions

GKH, ALOH and SW conceptualized and designed the study. Acquisition of data was performed by MBK, KGD, ALOH and SW. MBK and KGD analyzed and interpreted the data. MBK drafted the manuscript, and KGD, GKH, ALOH and SW revised the manuscript for intellectual content. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank all the patients who participated in this study.

Author details

¹Department of Physiotherapy, Oslo Metropolitan University, Oslo, Norway; ²Acute Psychiatric Department, Oslo University Hospital, Oslo, Norway; ³Department of Obstetrics and Gynecology, Oslo University Hospital, Oslo, Norway; ⁴Department of Dermatology, Oslo University Hospital, Oslo Norway; ⁵Department of Neurology, Oslo University Hospital, Oslo Norway.

References

1. Harlow BL, Kunitz CG, Nguyen RH, Rydell SA, Turner RM, MacLehose RF. Prevalence of symptoms consistent with a diagnosis of vulvodynia: population-based estimates from 2 geographic regions. *Am J Obstet Gynecol.* 2014;210(1):40 e1–8.
2. Gomez I, Coronado PJ, Martin CM, Alonso R, Guisasola-Campa FJ. Study on the prevalence and factors associated to vulvodynia in Spain. *Eur J Obstet Gynecol Reprod Biol.* 2019;240:121–4.
3. Vieira-Baptista P, Lima-Silva J, Cavaco-Gomes J, Beires J. Prevalence of vulvodynia and risk factors for the condition in Portugal. *Int J Gynecol Obstet.* 2014;127(3):283–7.
4. Reed BD, Legocki LJ, Plegue MA, Sen A, Haefner HK, Harlow SD. Factors associated with vulvodynia incidence. *Obstet Gynecol.* 2014;123(2 Pt 1):225–31.
5. Clare CA, Yeh J. Vulvodynia in adolescence: childhood vulvar pain syndromes. *J Pediatr Adolesc Gynecol.* 2011;24(3):110–5.
6. Bergeron S, Reed BD, Wesselmann U, Bohm-Starke N. Vulvodynia. *Nat Rev Dis Primers.* 2020;6(36).
7. Sadownik LA. Etiology, diagnosis, and clinical management of vulvodynia. *Int J Womens Health.* 2014;6:437–49.
8. Basson R, Driscoll M, Correia S. When sex is always painful: Provoked vestibulodynia. *B C Med J.* 2016;58(2):77–81.
9. Desrochers G, Bergeron S, Khalife S, Dupuis MJ, Jodoin M. Fear avoidance and self-efficacy in relation to pain and sexual impairment in women with provoked vestibulodynia. *Clin J Pain.* 2009;25(6):520–7.
10. Xie Y, Shi L, Xiong X, Wu E, Veasley C, Dade C. Economic burden and quality of life of vulvodynia in the United States. *Curr Med Res Opin.* 2012;28(4):601–8.
11. Benoit-Piau J, Bergeron S, Brassard A, Dumoulin C, Khalife S, Waddell G, Morin M. Fear-avoidance and Pelvic Floor Muscle Function are Associated with Pain Intensity in Women with Vulvodynia. *Clin J Pain.* 2018;34(9):804–10.
12. Dargie E, Gilron I, Pukall C. Provoked Vestibulodynia: A Comparative Examination of Mental Health, Sleep, Sexual Functioning, and Relationship Adjustment. *Clin J Pain.* 2017;33(10):870–76.
13. Aikens JE, Reed BD, Gorenflo DW, Haefner HK. Depressive symptoms among women with vulvar dysesthesia. *Am J Obst Gyn.* 2003;189(2):462–6.
14. Nylanderlundqvist E, Bergdahl J. Vulvar vestibulitis: evidence of depression and state anxiety in patients and partners. *Acta Derm Venereol.* 2003;83(5):369–73.
15. Shallcross R, Dickson JM, Nunns D, Mackenzie C, Kiemle G. Women's Subjective Experiences of Living with Vulvodynia: A Systematic Review and Meta-Ethnography. *Arch Sex Behav.* 2018;47(3):577–95.
16. Morin M, Carroll MS, Bergeron S. Systematic Review of the Effectiveness of Physical Therapy Modalities in Women With Provoked Vestibulodynia. *Sex Med Rev.* 2017;5(3):295–322.
17. Polpetta NC, Giraldo PC, Teatin Juliato CR, Gomes Do Amaral RL, Moreno Linhares I, Romero Leal Passos M. Clinical and therapeutic aspects of vulvodynia: the importance of physical therapy.

Minerva Ginecol. 2012;64(5):437–45.

18. Morin M, Dumoulin C, Bergeron S, Mayrand MH, Khalife S, Waddell G, et al. Multimodal physical therapy versus topical lidocaine for provoked vestibulodynia: a prospective, multicentre, randomized trial. *Am J Obstet Gynecol.* 2021;224(2):189.e1-189.e12.
19. Haugstad GK, Haugstad TS, Kirste UM, Leganger S, Wojniusz S, Klemmetsen I, et al. Posture, movement patterns, and body awareness in women with chronic pelvic pain. *J Psychosom Res.* 2006;61(5):637–44.
20. Haugstad GK, Haugstad TS, Kirste UM, Leganger S, Klemmetsen I, Malt UF. Mensendieck somatocognitive therapy as treatment approach to chronic pelvic pain: results of a randomized controlled intervention study. *Am J Obstet Gynecol.* 2006;194(5):1303–10.
21. Haugstad GK, Haugstad TS, Kirste UM, Leganger S, Wojniusz S, Klemmetsen I, Malt UF. Continuing improvement of chronic pelvic pain in women after short-term Mensendieck somatocognitive therapy: results of a 1-year follow-up study. *Am J Obstet Gynecol.* 2008;199(6):615 e1–8.
22. Haugstad GK, Wojniusz S, Kirschner R, Kirste U, Lilleheie I, Haugstad TS. Somatocognitive therapy of women with provoked vulvodynia: a pilot study. *Scand J Pain.* 2019;19(4):725–32.
23. Groven KS, Raheim M, Hakonsen E, Haugstad GK. "Will I ever be a true woman?" An exploration of the experiences of women with vestibulodynia. *Health Care Women Int.* 2016;37(8):818–35.
24. Fougner M, Haugstad GK. Treating gynaecological pain: the experiences of bachelor students in physiotherapy performing somatocognitive therapy. *Physiother Theory Pract.* 2015;31(5):318–26.
25. Chisari C, Monajemi MB, Scott W, Moss-Morris R, McCracken LM. Psychosocial factors associated with pain and sexual function in women with Vulvodynia: A systematic review. *Eur J Pain.* 2021;25(1):39–50.
26. Foster DC, Kotok MB, Huang LS, Watts A, Oakes D, Howard FM, et al. The tampon test for vulvodynia treatment outcomes research: reliability, construct validity, and responsiveness. *Obstet Gynecol.* 2009;113(4):825–32.
27. Stockdale CK, Lawson HW. 2013 Vulvodynia Guideline Update. *J Low Genit Tract Dis.* 2014;18:93–100.
28. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. *BMJ (Clinical research ed).* 2016;355.
29. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. *J Sex Marital Ther.* 2000;26(2):191–208.
30. Fernandes L, Storheim K, Lochting I, Grotle M. Cross-cultural adaptation and validation of the Norwegian pain catastrophizing scale in patients with low back pain. *BMC Musculoskelet Disord.* 2012;13:111.
31. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. *Behav Sci.* 1974;19(1):1–15.

32. Rost S, Van Ryckeghem DML, Koval P, Sütterlin S, Vögele C, Crombez G. Affective instability in patients with chronic pain: a diary approach. *Pain*. 2016;157(8):1783–90.
33. Pukall CF, Bergeron S, Brown C, Bachmann G, Wesselmann U, Group VCR. Recommendations for Self-Report Outcome Measures in Vulvodynia Clinical Trials. *Clin J Pain*. 2017;33(8):756–65.
34. De Andres J, Sanchis-Lopez N, Asensio-Samper JM, Fabregat-Cid G, Dolz VM. Peripheral subcutaneous vulvar stimulation in the management of severe and refractory vulvodynia. *Obstet Gynecol*. 2013;121(2 Pt 2 Suppl 1):495–8.
35. Phillips NA, Brown C, Foster D, Bachour C, Rawlinson L, Wan J, et al. Presenting symptoms among premenopausal and postmenopausal women with vulvodynia. *Menopause*. 2015;22(12):1296–300.
36. Brown C, Bachmann GA, Wan J, Foster D. Pain Rating in Women with Provoked Vestibulodynia: Evaluating Influence of Race. *J Womens Health*. 2016;25(1):57–62.
37. Brown CS, Bachmann GA, Wan J, Foster DC, Group GS. Gabapentin for the Treatment of Vulvodynia: A Randomized Controlled Trial. *Obstet Gynecol*. 2018;131(6):1000–7.
38. Foster DC, Kotok MB, Huang LS, Watts A, Oakes D, Howard FM, et al. Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial. *Obstet Gynecol*. 2010;116(3):583–93.
39. Guillet AD, Cirino NH, Hart KD, Leclair CM. Mindfulness-Based Group Cognitive Behavior Therapy for Provoked Localized Vulvodynia: A Randomized Controlled Trial. *J Low Genit Tract Dis*. 2019;23(2):170–5.
40. Lev-Sagie A, Kopitman A, Brzezinski A. Low-Level Laser Therapy for the Treatment of Provoked Vestibulodynia-A Randomized, Placebo-Controlled Pilot Trial. *J Sex Med*. 2017;14(11):1403–11.
41. Kvale S, Brinkman S. *Det kvalitative forskningsintervju (Interviews: Learning the craft of research interviewing)*. 2nd ed. ed. Oslo: Gyldendal Akademisk; 2009.
42. Haugstad GK, Wojniusz S, Kirschner R, Kirste U, Lilleheie I, Haugstad TS. Somatocognitive therapy of women with provoked vulvodynia: a pilot study. *Scand J Pain*. 2019;19(4):725–32.
43. Danielsen KG, Dahl-Michelsen T, Hakonsen E, Haugstad GK. Recovering from provoked vestibulodynia: Experiences from encounters with somatocognitive therapy. *Physiother Theory Pract*. 2018;23:1–10.
44. Haugstad GK, Wojniusz S, Kirste UM, Kirschner RS, Lilleheie I, Haugstad TS. Pain, psychological distress and motor pattern in women with provoked vestibulodynia (PVD) – symptom characteristics and therapy suggestions. *Scand J Pain*. 2018;18(2):221–27.
45. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *BMJ*. 2014;348:g1687.
46. Kaarbø MB, Danielsen KG, Haugstad GK, Helgesen ALO, Wojniusz S. The Tampon Test as a Primary Outcome Measure in Provoked Vestibulodynia: A Mixed Methods Study. *J Sex Med*. 2021;18(6):1083–91.

47. Kamper SJ, Ostelo RW, Knol DL, Maher CG, de Vet HC, Hancock MJ. Global Perceived Effect scales provided reliable assessments of health transition in people with musculoskeletal disorders, but ratings are strongly influenced by current status. *J Clin Epidemiol.* 2010;63(7):760-6.e1.
48. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol.* 2006;3(2):77–101.
49. Smith KB, Pukall CF, Chamberlain SM. Sexual and relationship satisfaction and vestibular pain sensitivity among women with provoked vestibulodynia. *J Sex Med.* 2013;10(8):2009–23.
50. Smith KB, Sadownik LA, Dargie E, Albert AYK, Brotto LA. Multidisciplinary Treatment for Provoked Vestibulodynia. *Clin J Pain.* 2019;35(4):335–44.
51. Rosen NO, Bergeron S, Pukall CF. Recommendations for the Study of Vulvar Pain in Women, Part 1: Review of Assessment Tools. *J Sex Med.* 2020;17(2):180–94.
52. Fernandes L, Storheim K, Lochting I, Grotle M. Cross-cultural adaptation and validation of the Norwegian pain catastrophizing scale in patients with low back pain. *BMC Musculoskelet Dis.* 2012;13:111.
53. Strand BH, Dalgard OS, Tambs K, Rognerud M. Measuring the mental health status of the Norwegian population: a comparison of the instruments SCL-25, SCL-10, SCL-5 and MHI-5 (SF-36). *Nord J Psychiatry.* 2003;57(2):113–8.

Figures

Figure 1

CONSORT 2010 Flow diagram. Design and flow of participants through study

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementarymaterial.docx](#)